Advice

Appropriate for use in NHS Scotland.

RECOMMENDATION

Compared with enoxaparin, fondaparinux has been shown to be associated with fewer thrombo-embolic events and a generally similar incidence of major bleeding. It is licensed for post-operative initiation, and this represents an advantage where regional anaesthesia and/or catheterisation are planned. It is predicted to be a cost effective alternative to enoxaparin in a robust economic model.

It may be considered for patients for whom antithrombotic therapy is appropriate, recognising that other antithrombotic agents and other approaches to prophylaxis may be more suitable in some situations.

Download detailed advice24KB (PDF)

Download

Medicine details

Medicine name:
fondaparinux (Arixtra)
SMC ID:
18/02
Indication:
Antithrombotic therapy
Pharmaceutical company
Sanofi-Aventis
BNF chapter
Cardiovascular system
Submission type
Full
Status
Accepted
Date advice published
08 November 2002